Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous infliximab maintained remission among patients with inflammatory bowel disease who ...
Down-titrating vial concentrations when restarting subcutaneous allergen immunotherapy after treatment gaps may help lower ...
Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...